Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAPPAC: Microbiota in Acute Appendicitis
NCT03257423Enrolling by invitation
- Sponsor
- Turku University Hospital
- Start
- Apr 2017
- Primary completion
- Dec 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, double-blind trial of ertapenem, levofloxacin, metronidazole and moxifloxacin in acute appendicitis (6 arms), sponsored by Turku University Hospital. Primary endpoint: Microbiology in the etiology of acute appendicitis at 1 day. Started Apr 2017; status: enrolling by invitation.
02
Drugs
ertapenemlevofloxacinmetronidazolemoxifloxacin
03
Conditions
acute appendicitis
Beyond the preview
Go deeper on NCT03257423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03257423.